..

Journal of AIDS & Clinical Research

ISSN: 2155-6113

Open Access

Durability and Tolerability of Fosamprenavir/Ritonavir Containing Regimens in HIV-Infected Patients with or without Hepatitis B or C Co-Infection: Results from a Large French Cohort in Clinical Practice

Abstract

Dellamonica P, Katlama C, Cabié A, Texier N and Finkielsztejn L

Background: We investigated whether tolerance and durability were different according to the presence or absence of co-infection (hepatitis B and/or hepatitis C virus) among a cohort of HIV-1 patients treated with fosamprenavir/r (FPV/r) containing regimen. Methods: Data were collected from 7 large HIV reference medical centers in France. We selected adult HIV-1 infected patients who were receiving an antiretroviral combination including FPV/r between January 2004 and December 2007. Date and reason for FPV/r discontinuation were recorded. Time to treatment discontinuation was analyzed by Kaplan Meier survival method. Results: In total, 1279 patients treated with FPV/r containing regimen were analysed in the study period out of them 20% were ART (antiretroviral therapy)-naive. 460 patients were hepatitis co-infected (13% are ART naive), 74% with HCV, 17% with HBV, 6% both. 263 co-infected patients (57.2%) and 469 mono-infected patients (57.2%) discontinued the FPV/r-including regimen after a median duration of 23 months, with no difference between coinfected and non-co-infected patients, at 23.2 months (95% CI 19.3-27.7) and 23.0 months (95% CI 20.3-25.5), respectively. Tolerability issues were the main reason for early discontinuation and among them gastro-intestinal (GI) adverse effects were the most frequent. Conclusion: In summary, antiviral therapy including FPV/r provides similar durability in HIV/HCV or HBV coinfected patients as in HIV mono-infected patients, for both naïve and experienced patients.

PDF

Share this article

Information

Copyright: This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


To cite this article:


Received Date: Jan 01, 1970
Accepted Date: Jan 01, 1970
Published Date: Jan 01, 1970

Recommended Conferences

Infectious Diseases and Control

New York, USA

Clinical Research & Clinical Trials

New York, USA
 
arrow_upward arrow_upward